Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on October 19, 2021. The filing reports significant changes in executive leadership, specifically the retirement of the Chief Executive Officer and the appointment of a new President and CEO.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
- Departure of CEO: Stephen Holcombe retired as Chief Executive Officer and employee effective October 19, 2021. He will transition to the role of Strategic Advisor to the CEO until December 31, 2022.
- Appointment of New CEO: Deepa Prasad was appointed President, Chief Executive Officer, and a member of the Board of Directors, effective October 19, 2021.
- Compensation Agreements:
- Mr. Holcombe: Entitled to a cash severance of $450,000 per year through December 31, 2022, a 2021 bonus, 12 months of medical coverage, and continued vesting of outstanding options. He will receive $150,000 per annum for consulting services.
- Ms. Prasad: Employment agreement through December 31, 2024, with a base salary of at least $650,000 and a target cash bonus of 100% of base salary. She received an inducement grant of options to purchase 2,498,635 shares at $1.47 per share, vesting on the third anniversary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is that payments under Mr. Holcombe's Retirement Agreement are conditioned on his release of claims and compliance with post-employment restrictive covenants. Ms. Prasad's employment agreement includes standard severance provisions for termination without "cause" or resignation for "good reason," including six months of base salary and COBRA coverage.
Investor Verification Checklist
- Verify the terms of the Retirement Agreement (Exhibit 10.1) regarding Mr. Holcombe's severance and consulting fees.
- Review the Prasad Employment Agreement (Exhibit 10.2) for specific performance targets tied to the 100% bonus.
- Examine the Inducement Award Agreement (Exhibit 10.3) for details on the vesting schedule and acceleration metrics for the 2,498,635 stock options granted to Ms. Prasad.
- Confirm the impact of the leadership transition on the company's strategic direction via the attached Press Release (Exhibit 99.1).